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Integration of Mental Health Screening in the Management of  
Temporomandibular Disorders (TMD)  
  
ABSTRACT  
  
Introduction  
  
 Common mental health disorders (CMD) such as anxiety and/or depression are 
reported ≥16-40% patients who suffer from Temporomandibular Disorders (TMD) 
against 16.3% in the general population. Failure to recognise CMD may be detrimental 
to the management of TMD. Paper-based screening tools have been reported in TMD, 
but require clinician assessment and subsequent collation of data.   
We present our findings of a new system – IMPARTS (Integrating Mental and Physical: 
Research Training and Services) – allowing the use of validated tools with treatment 
protocols to identify patients who may benefit from psychological intervention.  
IMPARTS also monitors disease and treatment progress.    
  
Method  
Patients attending outpatient clinics with symptoms of TMD completed a questionnaire 
of validated screening tools on an electronic tablet: Generalised Anxiety Disorder 
questionnaire (GAD-7), Patient Health Questionnaire (PHQ-9). Inclusion of Oral Health  
Impact Profile (OHIP-14) and Brief Pain Inventory (BPI) allowed treatment monitoring.  
Data collection and analysis linked directly into the electronic patient record. Results 
could be reviewed immediately during consultation with treatment suggestion – e.g. 
referral to liaison psychiatry.    
  
Results  
162 patients were included. 17.3% (n=28) screened positively for probable Major 
Depressive Disorder and 19.8% (n=32) for Generalised Anxiety Disorder requiring 
referral. 1.2% (n=2) were identified high risk of suicide/self-harm and recommended 
immediate psychological assessment.  
  
Discussion  
Patient-completed electronic screening tools with clearly defined protocols can aid 
holistic treatment of TMD through identification, risk stratification and appropriate 
referral of patients with CMD.   
  
Conclusion  
   
The early identification and concurrent management of CMD in TMD patients (≤2 years 
of symptoms) has the greatest benefit and is therefore essential.   
  
Keywords: Temporomandibular; TMD; mental health disorder; CMD; screening; 
electronic  
  
Introduction  
Temporomandibular disorders (TMD) are characterised by pain and dysfunction in the 
joint (TMJ) and/or the masticatory musculature.   
  
Psychological factors have been found to be an important aetiological component in 
producing and perpetuating TMJ disorders1-3. Clinical symptoms of common mental 
health disorders (CMD), such as depression and/or anxiety are reported in 16 -40% of 
TMD patients4-6 against 16.3% in the general population7. There is evidence that 
treatment of CMD is beneficial in the management of chronic health conditions and can 
reduce healthcare costs8. CMD is often under-diagnosed and under-treated9. NICE 
(National Institute for Health and Care Excellence) recommends screening for CMD for 
patients with chronic health conditions alongside a management strategy10.   
  
In the current climate it is difficult for Oral and Maxillofacial Surgery (OMFS) 
departments to make provision for the inclusion of a clinical psychologist or psychiatrist 
in the team, but non-mental health specialist clinicians often feel underqualified to make 
diagnoses or are unsure how to proceed with treatment9. Screening tools are available 
for CMD but these are often in paper form, time consuming to complete and analyse, and 
do not give guidance in management of a patient in the event of a positive screening 
result. We aim to show how this novel electronic screening tool can provide invaluable 
support to the non-mental health clinician to address CMD in TMD patients.  
  
Integrating Mental & Physical healthcare: Research, Training & Services (IMPARTS)11 is 
an initiative funded by King’s Health Partners (KHP) to integrate mental and physical 
healthcare in research, training and clinical services at Guy’s, St Thomas’ and King’s 
College hospitals, and the South London and Maudsley NHS Foundation Trust. It aims to 
improve mental healthcare provision within physical healthcare settings. The project 
supports non-mental health clinicians by providing an informatics system that facilitates 
routine collection of patient-reported outcomes, with real-time feedback to guide 
clinical care. The development of mental health care pathways for patients identified via 
the informatics system, allows timely and tailored, evidence-based care. The IMPARTS 
system creates a database that can be used for audit and research process and has 
ethical approval for this purpose. IMPARTS has been successfully implemented in a 
number of chronic conditions such as rheumatoid arthritis and inflammatory bowel 
disease, and found to be a feasible and acceptable way to integrate treatment for CMD 12.  
  
Materials and Methods  
Study population and design   
All patients referred to our OMFS specialist TMD clinics from both primary and 
secondary care between April 2015 and April 2016 were prospectively enrolled in the 
study. For the patient to be ultimately included in the analysis, electronic patient records 
were retrospectively checked to ensure the diagnosis of TMD was supported by the 
OMFS clinician at consultation as per the 2014 Research Diagnostic Criteria for  
Temporomandibular Disorders (RDC/TMD) of the International Association for Dental 
Research13. Those with symptoms attributable to other active pathology such as 
referred pain from a carious tooth were excluded. Patients had to be able to complete 
the questions themselves, although it was permitted to have an assistant read out 
questions and enter the answers given into the electronic tablet. The IMPARTS 
informatics system was used to develop a customised questionnaire for TMD patients 
that were delivered on an electronic tablet and completed by patients on arrival prior to 
their consultation, Figure 1. Responses linked directly and immediately into the 
electronic patient record. The results were reviewed and discussed with the patients by 
the clinician and pre-determined protocols used to guide treatment for patients who 
screened positive.   
  
IMPARTS questionnaires  
The custom designed IMPARTS questionnaire comprised a series of existing tools that 
have been widely validated for screening of CMD including depression, anxiety and 
suicidal ideation alongside disease specific tools. The screening tools used were the 
Patient Health Questionnaire-9 (PHQ-9), the Generalised Anxiety Disorder  
Questionnaire-7 (GAD-7), the Brief Pain Inventory (BPI) and the Oral Heath Impact  
Profile (OHIP-14).  Suicidal ideation was assessed by item 9 of the PHQ-9.  
  
Referral pathways were determined and agreed with existing psychiatric services for 
patients who screened positive for one or more mental health disorder (Figure 2).  With 
mild to moderate levels of depression and/or anxiety, the General Practitioner was 
notified of the result and referral to Improving Access to Psychological Therapies  
(IAPT)23 services recommended. IAPT is an NHS programme providing services across 
England offering interventions approved by NICE for treating people with depression 
and anxiety disorders. Severe depression and/or anxiety advised referral to liaison 
psychiatry, with an urgent referral in the cases of suicidal ideation.  A series of template 
letters was created to facilitate the referral process for clinicians. Information sheets on 
the study given to participating OMFS clinicians supplied the details of named local 
contacts.   
  
The IMPARTS system created a database that allowed data analysis for research 
purposes.   
  
Statistical analysis  
Descriptive statistics using the Independent t-test to compare normally distributed 
variables and Mann-Whitney and Wilcoxon signed-rank tests for non-parametric 
variables. Chi-square and Fisher’s exact tests were also used to compare subgroups. 
Spearman’s correlation coefficient, ρ, was used to measure association between different 
variables. The statistical analysis was performed with the Statistical Package for Social 
Sciences (SPSS, IBM Corp., Armonk, NY) version 23.0, with statistical significance set at 
0.05.  
  
Results  
The study included 162 patients with a total of 236 clinical encounters, over the 
12month period of the study.  19 patients were excluded from the study as their 
diagnosis was attributed to an alternative pathology at consultation. The patients were 
predominantly female (79.6%, F: M = 3.9:1), with a median age of 35 years (SD= 14.8, 
IQR 27-47]. 59 patients completed the IMPARTS questionnaire more than once during 
the study period, while the remaining 103 cases completed the questionnaire only once 
during the study period.   
TMD symptoms were present for more than 3 months prior to completion of the 
IMPARTS questionnaire in 145 patients, while only 8 had their symptoms for less than 3 
months.  The median duration of symptoms for the whole cohort on first completion of  
IMPARTS was 24 months (SD =72.6, IQR 12 - 60.5).  
  
The results of this study are summarised in Table 1. The median depression score was 6 
(SD=6.3). Severe depression and the probable MDD were higher in males than females 
but with no statistical significance (Table 1).  No symptoms of depression were found in  
11.7% of patients (n=19), while the majority of patients had either mild or moderate 
depressive symptoms (27.8% and 27.2% respectively).  
  
The median anxiety score was 4 (SD=5.2) with GAD suspected in 19.8% of patients 
(n=32). The majority of patients (n=87, 53.7%) did not have any symptoms suggestive of 
anxiety disorder, while moderate or severe symptoms were found in 11.7% and 8% of 
patients respectively.  
  
Co-morbidity and psychological distress is common; 11.1% of patients screened positive 
for MDD and GAD (n=18). 25.9% screened positive for MDD or GAD (n=42).  
  
Median OHIP-14 summary score was 29 (SD=11.7) with no significant difference 
between males and females. However, females had significantly higher scores in the 
OHIP-14 components of functional limitation, physical pain and physical disability 
(Table 1).  Median BPI score was 42 (SD=26.7), with females reporting slightly higher 
but not statistically significantly different scores to males (Table 1). A strong positive 
correlation was found between the initial BPI score and Depression, Anxiety and OHIP 
scores (ρ(160)=0.598, 0.499, 0.649 respectively, P<0.001).  
  
Referrals  
Sixty-two patients (38.3%) screened positive for CMD and were referred for fur ther 
management according to predetermined care pathways. Referral for mixed anxiety and 
depressive disorder occurred in 31 cases, while anxiety or depression alone was the 
reason for referral in 19 and 12 cases respectively. Forty patients screened positively for 
mild to moderate depression and/or anxiety that led to a template letter from the OMFS 
clinician to their General Practitioner recommending referral to IAPT services. 
Twentytwo cases had severe symptoms and triggered referral to liaison psychiatry , 
initiated by the OMFS clinician using a template referral letter.   
  
Suicidal ideation screened positive in 1.2% patients (n=2) and one case also screened 
positive for severe MDD. These cases were explored further by the OMFS clinician. The 
0.6% (n=1) patient who screened positively for suicidal ideation and severe MDD had an 
urgent referral made to liaison psychiatry. Following discussion with the patient, the 
other case was judged not to be an immediate risk, and a standard referral to liaison 
psychiatry was made.  
  
A total of 59 patients had a subsequent IMPARTS questionnaire completion at a followup  
during the study period. The median duration between the first and last IMPARTS 
questionnaire completion was 203 days (SD=118.1, IQR 109-308). Comparison between 
the initial and final scores shows some improvement in all four tools (PHQ-9, GAD-7, BPI 
and OHIP-14 scores) indicating a tendency for CMD to be less likely and for pain and 
OHRQoL to improve, as demonstrated in Figure 3. Improvement was mostly significant 
in patients who had TMD symptoms for ≤2years with a mean difference for PHQ-9, 
GAD7, OHIP-14 and BPI scores of 3.6 (p=0.033), 2.1 (p=0.013), 6.9 (p=0.007) and 18.7 
(p=0.007) respectively. This improvement was also limited to this category (≤ 2 years of 
symptoms) compared to the rest of the cohort in PHQ-9, OHIP-14 and BPI scores, 
3.7(p=0.023), 6 (p=0.02), 16.3 (p=0.012) respectively, Figure 4.) There was no 
significant difference in mean scores for those who had TMD symptoms for >5years 
prior to first IMPARTS questionnaire completion (Figure 3, 4).   
  
Patients satisfaction with IMPARTS  
The usefulness of completing IMPARTS questionnaires just before seeing the clinician 
was subjectively assessed in a representative sample of 71 patients. Forty-two patients 
(60%) answered “yes” when they were independently asked “Did you find it useful to 
complete the questionnaire before seeing the team?” There was no statistically 
significant clinical difference in anxiety, depression, OHRQOL or pain scores between the 
patients who found IMPARTS useful and the ones who did not.  
  
Discussion  
As expected, CMD are present in our patients at higher levels than the general 
population. Due to their recognised impact on TMD, CMD warrant specific attention. The 
use of the IMPARTS system allowed identification and further management of CMD to be 
easily integrated into the treatment plan for TMD by the non-mental health clinician.   
  
The PHQ-914-16 was chosen to screen for depression. Probable Major Depressive 
Disorder (MDD) was indicated if the patient reported low mood or loss of interest, in 
addition to a minimum of five of nine symptoms, on more than half the days in the last 
two weeks corresponding to a PHQ-9 score ≥10. Symptoms included items such as 
“trouble falling asleep, staying asleep or sleeping too much” and “feeling tired or having 
little energy”. Symptoms scored higher the more frequently they were experienced e.g. 0 
if the answer was “never” to a maximum of 3 for “nearly every day”. Suicidal ideation 
was assessed by item 9 of the PHQ-9 and defined as having “thoughts that you would be 
better off dead or of hurting yourself in some way” on more than half the days in the 
past two weeks. Anxiety was assessed using the GAD-717. Generalised Anxiety Disorder 
(GAD) was indicated if the patient scored ≥10. This was calculated using frequency (0 
“never” and a maximum of 3 for “nearly every day”) and symptoms such as “feeling 
nervous, anxious or on edge”. The BPI-short form18 has been used extensively for 
research in pain, and evaluates both severity of pain and impact on function. It was 
originally developed for use with cancer patients but has since evolved for use with 
noncancer pain also. It scores a scale of 0 (no pain or no interference) to 10 (worst pain 
imaginable or interferes completely). Example questions are “please choose the number 
that best describes your pain at its worst in the last week (0-10)” and “please choose the 
number that describes how, during the past week pain has interfered with your 
relations with others (0-10)”. The OHIP-1419-20 was chosen for its focus on oral 
healthrelated quality of life (OHRQoL) and has been used at national and international 
level for population based OHRQoL surveys, and more specifically in TMD21-22. It 
evaluates a number of domains including pain, function and psychological impact. Each 
question is scored for frequency from 0 “never”, to a maximum 4 “very often”. Example 
questions include “have you had painful aching in your mouth?” and “have you found it 
uncomfortable to eat any foods because of problems with your teeth, mouth or 
dentures?”.  
  
All questionnaires were chosen for their proven sensitivity, specificity and test-retest 
reliability in a wide variety of populations and across a number of different languages. 
The shortened versions were chosen as more user-friendly for patients screened, 
reducing time required and the number of questions asked, while still maintaining 
validity15, 16. The ubiquitous nature of these tools allows direct comparison with other 
national and international populations, and serial screenings can be used to review an 
individual patient’s progress and response to  treatment modalities.  
  
CMD of any subcategory are more common in females than males with a prevalence of  
19.7% vs. 12.5% in the general population7. This is important in the management of 
TMD due to female bias (F: M=3.9:1 in our population) and the prevalence of CMD 
remained higher in TMD patients even corrected for gender bias.  Probable MDD was 
suspected in 17.9% of patients (n=29), against 2.3% prevalence in the general 
population or 8.8% females only6 and GAD suspected in 19.8% of patients (n=32), 
against 4.4% prevalence in the general population or 12.8% females only7.   
  
It would be idyllic to include a clinical psychologist in every team treating patients with 
TMD; however budget constraints make this unlikely. The IMPARTS system delivers  a 
patient-completed electronically delivered screening tool that greatly facilitates the 
signposting of patients who may suffer from anxiety and/or depression and efficiently 
integrates mental healthcare into treatment for TMD.  
  
Clear guidance recommendations and pre-determined referral pathways with template 
referral letters reduces the burden on the OMFS clinician and General Practitioner in 
delivering holistic care. By integrating screening for CMDs we facilitate multidisciplinary 
care for patients with TMD to optimise outcomes and bring us in line with NICE 
guidelines.   
  
The data collected by the IMPARTS created database will be useful when service 
planning and provides powerful argument for added psychiatry and psychological 
support for OMFS units. The database is invaluable for data collection for assessment of 
patient symptoms and response to new treatment modalities.   
  
Conclusions  
IMPARTS is a useful screening tool to identify CMD in TMD patients and ensures easy 
integration into the management plan.   
  
Early identification and management of CMD in patients with TMD is essential. Our 
study shows improvements in CMD (≤2 years of TMD symptoms) has the greatest 
benefit in patient reported pain and OHRQoL.   
  
Serial screenings can be used to monitor response in patient-reported pain and OHRQoL 
to different treatment modalities.   
  
The IMPARTS system can be used as a powerful Audit and Research tool.  
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